Alkermes ALKS
Alkermes FY 2023: revenue $1.7B, up 50%; diluted EPS $2.10
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0000950170-24-017883
Key figures from this report
These are the numbers Alkermes reported for the year ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$1.7B+50% from $1.1B in FY 202210-K income statement, on EDGAR
- Net income$355.8MAgainst −$158.3M in FY 202210-K income statement, on EDGAR
- Diluted EPS$2.10Against −$0.97 in FY 202210-K income statement, on EDGAR
- Cash and cash equivalents$457.5M+56% from $292.5M in FY 2022Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations$401.4M+1807% from $21.0M in FY 202210-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Halozyme Therapeutics HALO public float $4.5B, Jun 30, 2025
- Axsome Therapeutics AXSM public float $4.4B, Jun 30, 2025
- Lantheus Holdings LNTH public float $4.3B, Jun 30, 2025
- Adma Biologics ADMA public float $4.2B, Jun 30, 2025
- Ionis Pharmaceuticals IONS public float $5.3B, Jun 30, 2025
